Cannabinoid hyperemesis syndrome, a paradoxical complication of chronic cannabis use, does not respond well to standard anti-nausea drugs like ondansetron. A 2025 expert review in Annals of Emergency Medicine recommends antidopaminergic agents such as haloperidol or droperidol as first-line emergency treatment, while emphasizing that cannabis cessation remains the only reliable path to lasting relief.

Cannabinoid hyperemesis syndrome is now outpacing gastroparesis and cyclic vomiting syndrome in emergency department frequency, and it received its own ICD-10 code in 2025. Yet many clinicians still reflexively reach for ondansetron, which appears to be an inferior choice for this specific condition. For patients who use cannabis therapeutically or recreationally, and for the physicians who advise them, understanding that CHS is mechanistically distinct from other causes of vomiting has immediate, practical consequences for treatment selection and patient counseling.

Cannabinoid hyperemesis syndrome is a cyclic vomiting disorder caused by chronic, heavy cannabis use, now recognized with its own ICD-10 code (F12.188) as of 2025. Despite superficial similarities to other causes of vomiting, CHS has a distinct pathophysiology involving CB1 receptor dysregulation in the hypothalamus and enteric nervous system, with secondary involvement of TRPV1 receptors. This mechanistic distinction is central to the review’s argument: because CHS is not driven by serotonergic pathways, standard serotonin-receptor antiemetics like ondansetron should not be expected to work as well as antidopaminergic agents. The review by Rech and colleagues consolidates this reasoning into a practical clinical framework, drawing on recent guideline recommendations from the American Gastroenterological Association and the GRACE-4 emergency medicine consensus.

The review’s key pharmacologic recommendation is that droperidol or haloperidol should serve as first-line ED treatments, supported by a small randomized controlled trial (n=33) showing haloperidol reduced nausea, abdominal pain, rescue antiemetic use, and time to discharge compared to ondansetron. A prospective cohort (n=47) demonstrated similar benefits for droperidol combined with diphenhydramine. Topical capsaicin showed benefit in a 30-patient pilot RCT, consistent with its TRPV1 mechanism. The authors emphasize that cannabis cessation remains the only intervention associated with durable remission, though symptom resolution may take 7 to 10 days and full remission up to three months. The authors consistently acknowledge the low quality of the evidence base, noting that higher-powered trials are needed to confirm these recommendations.

Not Your Usual Nausea: Why CHS Demands a Different Drug and a Different Conversation

Every emergency physician has seen the patient who comes back again and again, vomiting relentlessly, cannabis in their history, ondansetron in their IV, and nothing getting better. That cycle has a name, a mechanism, and a better treatment, but only if you know to look for it. The 2025 review by Rech and colleagues in Annals of Emergency Medicine is not a randomized trial, and it does not pretend to be. It is an expert synthesis of genuinely thin evidence, and its most important contribution is not a specific drug recommendation but a conceptual reorientation: CHS is not garden-variety nausea, and treating it as such is not a neutral default. It is an active clinical error. The paper correctly identifies that CB1 receptor dysregulation and TRPV1 involvement create a pathophysiologic landscape where serotonergic antiemetics are the wrong key for the lock. That framing is mechanistically sound and aligns with what I see in clinical practice. However, the evidence supporting specific alternatives, primarily a 33-patient RCT for haloperidol and a 47-patient cohort for droperidol, is about as sturdy as diagnosing a roof leak by watching which corner gets wet in a light drizzle. Directionally useful, but not the foundation for a major renovation. The review earns real credit for its honesty about this limitation, and for grounding its recommendations in guideline alignment rather than overclaiming from small trials.

Where the paper overreaches is in its discussion of erector spinae plane block, where the authors transition from evidence synthesis to personal anecdote, noting they have “successfully utilized” the technique without any CHS-specific peer-reviewed data. For an otherwise careful document, this departure is notable. I would tell a colleague that it is worth being aware of the technique but not worth incorporating into a second-line protocol until controlled data exist. Similarly, the amitriptyline recommendation for prophylaxis is extrapolated from a cyclic vomiting syndrome study in cannabis users, not from CHS-specific research. Using a key that opens a similar-looking door to try unlocking a different lock might work, but the mechanisms are different enough that we should not be surprised if it does not fit. These are not fatal flaws, but they are the kind of inferential stretches that a busy clinician reading quickly might absorb as settled fact.

What I would say to a patient is straightforward: your symptoms are caused by your cannabis use, we have medications that work better than the usual anti-nausea drugs for this specific condition, and the only thing that will reliably prevent these episodes from recurring is stopping cannabis. What I would say to a policymaker is equally direct: CHS is a growing public health consequence of cannabis liberalization, and the research needed to optimize care has been systematically obstructed by Schedule I classification barriers. When a condition is mechanistically distinct from superficially similar disorders, defaulting to the standard of care for those similar disorders is not neutral. It is an active clinical error. CHS teaches us that understanding why patients are sick, not just what their symptoms look like, must drive treatment selection.

This review sits at a pivotal moment in the research arc for CHS. The condition has moved from case-report curiosity to recognized clinical entity with its own ICD-10 code, yet the treatment evidence remains at the small-trial and case-series level. The alignment of this review’s recommendations with both the 2024 AGA guidelines and the GRACE-4 consensus provides a degree of cross-validation, but guideline concordance does not independently elevate the quality of the underlying primary evidence. Clinicians should treat these recommendations as the best available expert opinion, not as established standard of care.

From a pharmacologic standpoint, haloperidol and droperidol carry their own safety considerations, including QTc prolongation, extrapyramidal symptoms, and sedation. The review recommends concurrent diphenhydramine with droperidol to mitigate dystonic reactions, which is a practical and evidence-informed approach. Drug interactions deserve particular attention in patients taking other QTc-prolonging medications, and in oncology patients where antiemetic regimens may already be complex. For clinicians in cannabinoid medicine, the most actionable recommendation is this: when a patient presents with a pattern of cyclic vomiting and heavy cannabis use, flag CHS early, communicate clearly that standard antiemetics are likely insufficient, and begin the cessation conversation before discharge rather than after the next readmission.

This is an expert narrative clinical review published under the Toxicology/Expert Clinical Management section of Annals of Emergency Medicine. It occupies a lower tier in the evidence hierarchy than systematic reviews, meta-analyses, or clinical practice guidelines, though it draws on and aligns with several of these. No systematic search methodology is described, which means the selection of cited studies is subject to author discretion and potential bias. The single most important inference constraint is that the treatment recommendations rest almost entirely on studies with sample sizes between 30 and 48 participants, none of which are adequately powered to establish definitive clinical superiority.

This review confirms and consolidates the directional shift that the 2024 AGA clinical guidelines and the GRACE-4 emergency medicine consensus have already signaled: antidopaminergic agents should replace serotonergic antiemetics as first-line treatment for CHS. The original description by Allen and colleagues in 2004, which first characterized the syndrome in a case series of chronic cannabis users in Australia, established the clinical phenotype that this review builds on two decades later. What has changed is the pharmacologic framework: the mechanistic reasoning linking CB1 receptor dysregulation to dopaminergic pathway involvement provides a rationale that earlier case-report literature lacked. The review extends the existing literature by incorporating special population guidance and novel interventions like capsaicin and erector spinae plane block, though the latter remains without CHS-specific evidence.

The most consequential analytic choice in this review is the decision to present treatment recommendations as a unified hierarchy rather than stratifying them by evidence quality. A systematic review with formal quality appraisal of each cited study, such as GRADE assessment, would likely have resulted in very low certainty ratings for nearly every pharmacologic recommendation, potentially changing the tone from “recommended first-line” to “suggested with very low confidence.” Additionally, had the authors conducted a quantitative synthesis of available trial data, the small sample sizes and heterogeneous outcome measures might have yielded imprecise pooled estimates that would not support the confident hierarchical framing the review employs. The practical recommendations might have remained the same in direction, but the strength of language surrounding them would almost certainly have been more cautious.

The most likely overinterpretation is treating this expert narrative review as though it carries the evidentiary weight of a systematic review or high-certainty clinical practice guideline. Its practical format, complete with dosing tables and treatment hierarchies, lends an impression of settled science that the underlying evidence does not support. The haloperidol and droperidol recommendations rest on studies with 33 and 47 participants, respectively, which are too small to rule out inflated effect estimates or to detect uncommon adverse events. Similarly, the erector spinae plane block discussion may be read as an evidence-based recommendation when it is, by the authors’ own admission, extrapolated from visceral pain literature and personal anecdotal experience. Readers should preserve every caveat the authors included and resist the temptation to strip the hedging from these recommendations when communicating them to patients or colleagues.

This expert review contributes a practical, mechanistically grounded synthesis of CHS diagnosis and ED management that aligns with current professional guidelines. It does not establish high-certainty treatment efficacy for any specific intervention, as the entire evidence base rests on small trials and case series. For practice now, it means emergency clinicians should reach for haloperidol or droperidol before ondansetron when CHS is suspected, offer capsaicin as an adjunct, and prioritize the cessation conversation at every visit.

What is cannabinoid hyperemesis syndrome?

CHS is a condition in which chronic, heavy cannabis use paradoxically causes episodes of severe, cyclic vomiting. It is distinct from other causes of nausea because it is driven by cannabis-related changes in receptors in the brain and gut. A hallmark feature is that hot showers or baths provide temporary relief. The condition resolves with cannabis cessation, though symptoms may take one to three months to fully clear.

Why doesn’t the usual anti-nausea medication work for CHS?

Standard anti-nausea medications like ondansetron work by blocking serotonin receptors, but CHS appears to involve a different pathway, primarily dopamine receptors. This is why medications like haloperidol and droperidol, which target dopamine receptors, appear to be more effective. Think of it as needing a different key for a different lock: the symptoms may look similar to other causes of vomiting, but the underlying mechanism requires a different pharmacologic approach.

Does this mean I have to stop using cannabis entirely?

Cannabis cessation is the only intervention consistently shown to produce lasting remission from CHS episodes. The review acknowledges that permanent abstinence is unrealistic for some patients and suggests a graduated, multidisciplinary approach to cessation. Some clinicians discuss transitioning to lower-potency products or edibles as a harm-reduction step, but this strategy has not been specifically studied in CHS populations and should be undertaken with professional guidance.

How strong is the evidence behind these treatment recommendations?

The evidence is real but limited. The largest studies cited in this review enrolled between 30 and 48 participants, and no large, definitive trials have been completed. The recommendations align with professional guidelines from the American Gastroenterological Association and emergency medicine consensus panels, which adds credibility, but the field still needs larger, well-controlled studies to confirm the best treatments and determine how well they work across different patient populations.

Have thoughts on this? Share it: